Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd.

November 13, 2008 09:00 ET

Urodynamix and Pfizer Inc. Launch Promotional Program in Boston

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 13, 2008) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) and Pfizer Inc. today begin a series of promotional programs to increase awareness of uroNIRS™ Bladder Monitor technology among urologists, medical professionals, and key opinion leaders. The first session in the series will be held in Boston, MA with subsequent events scheduled to be held in New York, NY, Philadelphia, PA, and Washington, DC in December 2008. Urodynamix and Pfizer Inc. plan further sessions across the US beginning in January 2009.

These programs will be coordinated by Pfizer's Urology division and will feature various keynote speakers. In Boston, Dr. Alexis Te, MD, Associate Professor of Urology at Cornell University will introduce Urodynamix's uroNIRS™ technology, a non-invasive medical device that uses near infrared spectroscopy (NIRS) for the functional evaluation of the bladder to aid in the diagnosis and treatment of lower urinary tract symptoms (LUTS). Dr. Te will discuss the results of his work using NIRS over the past six months in addition to previous published research.

"We are very excited about the opportunity to collaborate with Pfizer and our leading distribution partners to deliver the message about UroNIRS™ products," said Barry Allen, President and CEO of Urodynamix.

About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, erectile dysfunction, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

About Pfizer Inc.

Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company. Pfizer is taking new approaches to advancing better health as it discovers, develops, manufactures and delivers quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. For more information visit www.pfizer.com.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information